BAKER BROS. ADVISORS LP — 13F Holdings & Portfolio
CIK 1263508 · latest 13F-HR filed 2026-08-14
BAKER BROS. ADVISORS LP manages $19.96B in 13F-reported U.S. long-equity assets across 84 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are INCY (17.48%), ONC (12.57%), RVMD (10.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 8 new positions and exited 8; 48 existing positions rose in reported value and 17 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 72.8%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 27, 2026.
NEW YORK, NY 10014
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BAKER BROS. ADVISORS (GP), LLC Control | GENERAL PARTNER since Jan 2000 | Less than 5% | Domestic Entity |
| BAKER, FELIX, JAMES Control | LIMITED PARTNER since Jan 2000 | 25–50% | Individual |
| BAKER, JULIAN, CHARLES Control | LIMITED PARTNER since Jan 2000 | 25–50% | Individual |
| LESSING, SCOTT, LAWRENCE Control | PRESIDENT, CHIEF COMPLIANCE OFFICER since Feb 2011 | Less than 5% | Individual |
| TOOHEY, ALEXANDRA, ANN Control | CHIEF FINANCIAL OFFICER since Jan 2014 | Less than 5% | Individual |
| BAKER, FELIX, JAMES Control Indirect owner via BAKER BROS. ADVISORS (GP), LLC | MANAGING MEMBER since Jan 2000 | 50–75% | Individual |
| BAKER, JULIAN, CHARLES Control Indirect owner via BAKER BROS. ADVISORS (GP), LLC | MANAGING MEMBER since Jan 2000 | 50–75% | Individual |
Ownership & leadership changes · 4 filings with changes since Feb 13, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedBAKER, FELIX, JAMES · title CO-MANAGING MEMBER → LIMITED PARTNER
- ChangedBAKER, FELIX, JAMES · indirect via BAKER BROS. ADVISORS (GP), LLC: title MEMBER → MANAGING MEMBER
- ChangedBAKER, JULIAN, CHARLES · title CO-MANAGING MEMBER → LIMITED PARTNER
- ChangedBAKER, JULIAN, CHARLES · indirect via BAKER BROS. ADVISORS (GP), LLC: title MEMBER → MANAGING MEMBER
- ChangedBAKER BROS. ADVISORS (GP), LLC · now a control person
- AddedBAKER BROS. ADVISORS (GP), LLC · GENERAL PARTNER · Less than 5%
- AddedBAKER, FELIX, JAMES · MEMBER · 50–75% · indirect via BAKER BROS. ADVISORS (GP), LLC · control person
- AddedBAKER, JULIAN, CHARLES · MEMBER · 50–75% · indirect via BAKER BROS. ADVISORS (GP), LLC · control person
- ChangedBAKER, FELIX, JAMES · ownership 50–75% → 25–50%
- ChangedBAKER, JULIAN, CHARLES · ownership 50–75% → 25–50%
- No longer listedKIRBY, LEO, EDWARD · CHIEF FINANCIAL OFFICER · Less than 5% · listed since Jan 2002
- AddedTOOHEY, ALEXANDRA, ANN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ListedBAKER, FELIX, JAMES · CO-MANAGING MEMBER · 50–75% · control person
- ListedBAKER, JULIAN, CHARLES · CO-MANAGING MEMBER · 50–75% · control person
- ListedKIRBY, LEO, EDWARD · CHIEF FINANCIAL OFFICER · Less than 5%
- ListedLESSING, SCOTT, LAWRENCE · PRESIDENT, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Revolution Medicines, Inc.$1.21B +130.6%
- Incyte Corporation$593.6M +20.5%
- Kymera Therapeutics, Inc.$271.7M +37.7%
- Alkermes plc$170.6M +48.2%
- AbCellera Biologics Inc.$153.5M +145.3%
Top Trims
- Insmed Incorporated-$275.7M -22.7%
- Summit Therapeutics Inc.-$212.3M -30.8%
- Celcuity Inc.-$75.4M -8.3%
- Edgewise Therapeutics, Inc.-$56.7M -27.4%
- Entrada Therapeutics, Inc.-$26.7M -41.7%
New Positions
- Faeth Therapeutics, Inc.$32.2M
- Cytokinetics, Incorporated$18.0M
- Intellia Therapeutics, Inc.$15.7M
- Parabilis Medicines, Inc.$13.7M
- Avalyn Pharma Inc.$11.5M
Exited Positions
- Abivax S.A.$97.5M
- Spyre Therapeutics, Inc.$50.4M
- Centessa Pharmaceuticals plc$26.6M
- Immunocore Holdings plc$22.1M
- Contineum Therapeutics, Inc.$18.6M
BAKER BROS. ADVISORS LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Incyte Corporation | INCY | 45337C102 | $3.49B | 17.48% | 30,762,330 | SH |
| 2 | BeOne Medicines Ltd. | ONC | 07725L102 | $2.51B | 12.57% | 8,801,567 | SH |
| 3 | Revolution Medicines, Inc. | RVMD | 76155X100 | $2.14B | 10.74% | 11,443,357 | SH |
| 4 | Madrigal Pharmaceuticals, Inc. | MDGL | 558868105 | $1.15B | 5.77% | 2,143,131 | SH |
| 5 | ACADIA Pharmaceuticals Inc. | ACAD | 004225108 | $1.09B | 5.44% | 42,912,904 | SH |
| 6 | Kymera Therapeutics, Inc. | KYMR | 501575104 | $992.7M | 4.97% | 8,657,242 | SH |
| 7 | Insmed Incorporated | INSM | 457669307 | $937.8M | 4.70% | 8,796,111 | SH |
| 8 | Celcuity Inc. | CELC | 15102K100 | $828.2M | 4.15% | 7,915,792 | SH |
| 9 | Kodiak Sciences Inc. | KOD | 50015M109 | $776.1M | 3.89% | 19,919,186 | SH |
| 10 | Rhythm Pharmaceuticals, Inc. | RYTM | 76243J105 | $622.3M | 3.12% | 5,604,483 | SH |
| 11 | Praxis Precision Medicines, Inc. | PRAX | 74006W207 | $587.0M | 2.94% | 1,753,198 | SH |
| 12 | Alkermes plc | ALKS | G01767105 | $524.6M | 2.63% | 10,012,267 | SH |
| 13 | Summit Therapeutics Inc. | SMMT | 86627T108 | $477.7M | 2.39% | 32,786,348 | SH |
| 14 | GRAIL, Inc. | GRAL | 384747101 | $275.0M | 1.38% | 4,028,614 | SH |
| 15 | AbCellera Biologics Inc. | ABCL | 00288U106 | $259.1M | 1.30% | 33,012,138 | SH |
| 16 | Immunovant, Inc. | IMVT | 45258J102 | $209.4M | 1.05% | 5,435,220 | SH |
| 17 | IDEAYA Biosciences, Inc. | IDYA | 45166A102 | $186.7M | 0.94% | 5,010,030 | SH |
| 18 | Kiniksa Pharmaceuticals International, plc | KNSA | G52694109 | $181.3M | 0.91% | 2,834,643 | SH |
| 19 | Roivant Sciences Ltd. | ROIV | G76279101 | $166.9M | 0.84% | 4,716,831 | SH |
| 20 | Arrowhead Pharmaceuticals, Inc. | ARWR | 04280A100 | $162.4M | 0.81% | 1,992,783 | SH |
| 21 | Ionis Pharmaceuticals, Inc. | IONS | 462222100 | $162.4M | 0.81% | 2,047,727 | SH |
| 22 | Edgewise Therapeutics, Inc. | EWTX | 28036F105 | $150.4M | 0.75% | 3,701,719 | SH |
| 23 | Replimune Group, Inc. | REPL | 76029N106 | $122.3M | 0.61% | 11,045,336 | SH |
| 24 | Nurix Therapeutics, Inc. | NRIX | 67080M103 | $113.0M | 0.57% | 4,658,556 | SH |
| 25 | Stoke Therapeutics, Inc. | STOK | 86150R107 | $109.2M | 0.55% | 3,336,697 | SH |
| 26 | Monte Rosa Therapeutics, Inc. | GLUE | 61225M102 | $105.2M | 0.53% | 4,345,736 | SH |
| 27 | Immatics N.V. | IMTX | N44445109 | $96.3M | 0.48% | 9,508,565 | SH |
| 28 | Denali Therapeutics Inc. | DNLI | 24823R105 | $96.0M | 0.48% | 3,734,336 | SH |
| 29 | Crinetics Pharmaceuticals, Inc. | CRNX | 22663K107 | $88.0M | 0.44% | 2,351,465 | SH |
| 30 | Dianthus Therapeutics, Inc. | DNTH | 252828108 | $83.1M | 0.42% | 852,164 | SH |
| 31 | Structure Therapeutics Inc. | GPCR | 86366E106 | $76.9M | 0.39% | 1,432,529 | SH |
| 32 | Celcuity Inc. | CELC | 15102KAA8 | $69.2M | 0.35% | 30,750,000 | PRN |
| 33 | Rapport Therapeutics, Inc. | RAPP | 75383L102 | $64.5M | 0.32% | 1,547,090 | SH |
| 34 | Alumis Inc. | ALMS | 022307102 | $56.6M | 0.28% | 2,012,500 | SH |
| 35 | Prelude Therapeutics Inc. | PRLD | 74065P101 | $54.0M | 0.27% | 10,123,824 | SH |
| 36 | Relay Therapeutics, Inc. | RLAY | 75943R102 | $52.9M | 0.27% | 2,826,783 | SH |
| 37 | Mirum Pharmaceuticals, Inc. | MIRM | 604749101 | $52.2M | 0.26% | 445,975 | SH |
| 38 | Bicycle Therapeutics plc | BCYC | 088786108 | $46.2M | 0.23% | 10,885,357 | SH |
| 39 | Enliven Therapeutics, Inc. | ELVN | 29337E102 | $45.9M | 0.23% | 905,191 | SH |
| 40 | Celldex Therapeutics, Inc. | CLDX | 15117B202 | $44.0M | 0.22% | 1,182,611 | SH |
| 41 | Viridian Therapeutics, Inc. | VRDN | 92790C104 | $43.8M | 0.22% | 2,383,025 | SH |
| 42 | Design Therapeutics, Inc. | DSGN | 25056L103 | $38.8M | 0.19% | 2,678,430 | SH |
| 43 | Entrada Therapeutics, Inc. | TRDA | 29384C108 | $37.3M | 0.19% | 5,072,730 | SH |
| 44 | Faeth Therapeutics, Inc. | FTH | 81728A207 | $32.2M | 0.16% | 1,286,411 | SH |
| 45 | Aktis Oncology, Inc. | AKTS | 01021M104 | $32.1M | 0.16% | 996,351 | SH |
| 46 | Neurogene Inc. | NGNE | 64135M105 | $31.2M | 0.16% | 991,691 | SH |
| 47 | Jade Biosciences, Inc. | JBIO | 008064206 | $27.3M | 0.14% | 1,230,426 | SH |
| 48 | Taysha Gene Therapies, Inc. | TSHA | 877619106 | $27.3M | 0.14% | 4,004,756 | SH |
| 49 | Arcus Biosciences, Inc. | RCUS | 03969F109 | $26.0M | 0.13% | 844,816 | SH |
| 50 | Disc Medicine, Inc. | IRON | 254604101 | $25.6M | 0.13% | 349,657 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $19.96B | 84 | 0001104659-26-097191 |
| 2026-03-31 | 2026-05-15 | $17.42B | 84 | 0001104659-26-062547 |
| 2025-12-31 | 2026-02-17 | $17.08B | 86 | 0001104659-26-016374 |
| 2025-09-30 | 2025-11-14 | $13.84B | 91 | 0001104659-25-112595 |
3RD FLOOR
NEW YORK, NY 10014